Belgium's Devgen spins off new company with kinase inhibitor assets
This article was originally published in Scrip
Executive Summary
Devgen has spun off certain assets and intellectual property from its former pharma division into a new company called Amakem. The start-up received €1.5 million in seed financing from LRM (a Flemish investment company), Life Sciences Research Partners (LSRP; a non-profit Belgium organisation focused on supporting the innovation) and VINNOF (a Flemish innovation fund).